Abivax Announces Termination of Liquidity
Contract and Publishes End of Contract Statement
PARIS, France, October 11, 2024, 6:00 p.m. (CEST) - Abivax SA (Euronext Paris & Nasdaq: ABVX) ("Abivax" or the "Company"), aclinical-stagebiotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients witch chronic inflammatory diseases, today announced that it has ended the liquidity contract signed on February 4, 2019 with TRADITION SECURITIES AND FUTURE (TSAF SA). The termination is effective from September 30, 2024, after the close of Euronext market.
On the termination date of this contract, the following assets appeared on the liquidity account:
- 0 shares
- €434,377.26 in cash
As a reminder, for the latest half-year statement as of June 30, 2024, the following assets appeared on the liquidity account:
- 11,431 shares
- €313,753.00 in cash
And between July 1st, 2024, and September 30, 2024, included:
|
Buy side |
Traded volume : |
€12,014.60 |
10 transactions |
|
1,070 shares |
|||
|
Sell side |
Traded volume : |
€132,638.86 |
26 transactions |
|
12,501 shares |
|||
Moreover, the following resources were allocated to the liquidity contract for its implementation beginning June 26th, 2015 (date of the initial contract entered into between the Company and TSAF SA, which was replaced by the above-mentioned contract):
- 0 shares
- €1,000,000 in cash
The liquidity account returned €500,000.00 in cash to Abivax on April 15, 2020.
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S., Abivax' s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on X, formerly Twitter, @ABIVAX.
|
Contacts |
||
|
Abivax |
Investor Relations France |
Abivax |
|
Finance department |
Seitosei ● Actifin |
Investor Relations |
|
Didier Blondel |
Ghislaine Gasparetto |
Patrick Malloy |
|
didier.blondel@abivax.com |
ghislaine.gasparetto@seitosei- |
patrick.malloy@abivax.com |
|
+33 1 53 83 08 41 |
actifin.com |
+1 847 987 4878 |
|
+33 6 21 10 49 24 |
Attachments
Disclaimer
Abivax SA published this content on October 11, 2024, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on October 11, 2024 at 18:01:24.213.